• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ForDoz enters manufacturing agreement with LipoMedix

February 19, 2021 By Sean Whooley

ForDoz Pharma announced today that it entered into an agreement with LipoMedix to manufacture its lead compound for a clinical trial.

LipoMedix’s pegylated liposomal Promitil (PL-MLP) is designed for the selective delivery of the therapeutic agent to cancer-affected tissues and is suited for cancer chemoradiotherapy, according to a news release.

Studies have shown PL-MLP to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug-resistant tumors, the companies say.

“We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a low-toxicity and effective treatment option,” LipoMedix president & chief scientific officer Dr. Alberto Gabizon said in the release. “We are thinking long term when selecting our partnerships and look forward to partnering with ForDoz on the next phase of our journey to bring Promitil to those who need it most.”

East Windsor, N.J.-based ForDoz is a specialty pharmaceutical company focusing on developing, manufacturing and commercializing value-added sterile and complex injectable products, including liposomes, microspheres, micelles, nanosuspensions and microcrystal-suspensions.

“Our mission is to ultimately aid in the delivery of innovative medicines that will help people live longer and better lives,” ForDoz founder & CEO James He said. “We are proud to partner with LipoMedix to help them develop and manufacture Promitil here in the United States.”

Filed Under: Business/Financial News, Contract Services, Featured, Oncology, Pharmaceuticals Tagged With: ForDoz, LipoMedix

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS